PDA Announces 2008 Board of Directors and Officers
The Parenteral Drug Association (PDA, Bethesda, MD) has announced its 2008 board of directors and officers.
The Parenteral Drug Association (PDA, Bethesda, MD), has announced its 2008 board of directors and officers.
The newly elected officers for 2008–2009 are: Chair, John Shabushnig, Pfizer Inc.; Chair-Elect, Maik Jornitz, Sartorius Stedim Biotech; Secretary, Rebecca Devine, Regulatory Consultant; and Treasurer, Anders Vinther, Genentech, Inc. The 2006–2007 Chair, Vincent Anicetti, Genentech, Inc., assumes the office of Immediate Past Chair.
Laura Thoma, University of Tennesee, was reelected for a second term as a director. In addition, there are five new directors joining PDA’s board, including: Harold Baseman, ValSource LLC; Véronique Davoust, Pfizer Inc.; Lothar Hartmann, Hoffman-La Roche; Stefan Köhler, AstraZeneca; and Michael Sadowski, Baxter Healthcare Corporation.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
